BiotechTube

Simufilam

Phase 1Completed
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hepatic Insufficiency

Conditions

Hepatic Insufficiency

Trial Timeline

Jun 26, 2024 → Dec 7, 2024

NCT ID
NCT06390410

About Simufilam

Simufilam is a phase 1 stage product being developed by Cassava Sciences for Hepatic Insufficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT06390410. Target conditions include Hepatic Insufficiency.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (5)

NCT IDPhaseStatus
NCT06390410Phase 1Completed
NCT06195319Phase 1Completed
NCT05575076Phase 3Terminated
NCT05352763Phase 2Terminated
NCT04932655Phase 1Completed

Competing Products

20 competing products in Hepatic Insufficiency

See all competitors
ProductCompanyStageHype Score
ITF2357BiotrialPhase 1
25
GB1211 + PlaceboComac MedicalPhase 1/2
33
ACT-541468 25 mg + ACT-541468 25 mg (or 10 mg depending on interim results)IdorsiaPhase 1
28
OlomorasibEli LillyPhase 1
33
cisplatin + gemcitabine hydrochlorideEli LillyPhase 3
77
exatecan mesylateDaiichi SankyoPhase 2
52
DS-3201bDaiichi SankyoPhase 1
33
QuizartinibDaiichi SankyoPhase 1
33
QuizartinibDaiichi SankyoPhase 1
33
PexidartinibDaiichi SankyoPhase 1
33
Tivantinib + Tivantinib + Tivantinib + TivantinibDaiichi SankyoPhase 1
33
BocidelparAstellas PharmaPhase 1
33
fezolinetantAstellas PharmaPhase 1
33
enzalutamideAstellas PharmaPhase 1
33
ASP015KAstellas PharmaPhase 1
33
ASP2215Astellas PharmaPhase 1
33
BPN14770ShionogiPhase 1
33
S-217622ShionogiPhase 1
33
LemborexantEisaiPhase 1
33
LenvatinibEisaiPhase 1
33

Other Products from Cassava Sciences

Simufilam + PlaceboPhase 3
69
SimufilamPhase 3
69
Simufilam + PlaceboPhase 3
69
Placebo oral tablet + Simufilam 100 mg tablet + Simufilam 50 mg oral tabletPhase 2
44
Simufilam 100 mg oral tablet + PlaceboPhase 2
44